{"id":23218,"date":"2023-01-03T19:44:00","date_gmt":"2023-01-03T11:44:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23218"},"modified":"2025-01-26T19:48:57","modified_gmt":"2025-01-26T11:48:57","slug":"hengrui-pharmaceuticals-appoints-dr-jiang-ningjun-as-deputy-general-manager-and-cso","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23218","title":{"rendered":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO"},"content":{"rendered":"\n

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276<\/a>) has announced the appointment of Dr. “Frank” Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm’s future strategy and research and development (R&D) layout.<\/p>\n\n\n\n

Dr. Jiang’s Background and Experience<\/strong>
Dr. Jiang is a graduate of Nanjing Medical University and holds a doctorate degree in Immunology from the University of British Columbia, Canada. He completed his post-doc work at the University of Washington Medical School. Dr. Jiang rose to the position of global vice-president and Asia-Pacific R&D head at Sanofi before leaving the French giant in 2016 to become chairman and CEO of CStone Pharmaceuticals (HKG: 2616<\/a>). Under his leadership, CStone successfully debuted on the Hong Kong stock exchange in 2019 and achieved market approvals for four different cutting-edge products. Dr. Jiang decided to retire from his post in August 2022.<\/p>\n\n\n\n

Impact on Hengrui’s Strategy and Development<\/strong>
The appointment of Dr. Jiang Ningjun as CSO is expected to significantly enhance Hengrui Medicine’s strategic capabilities. His extensive experience in R&D and business leadership will provide valuable insights and direction for Hengrui’s future growth. As the company continues to expand its pipeline and focus on innovative therapies, Dr. Jiang’s expertise will be instrumental in driving Hengrui’s mission to improve patient outcomes and address significant unmet medical needs.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,188,2586,856,852],"class_list":["post-23218","post","type-post","status-publish","format-standard","hentry","category-company","tag-biotech","tag-cstone-pharmaceuticals","tag-hengrui-pharmaceuticals","tag-hkg-2616","tag-sha-600276"],"yoast_head":"\nHengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. "Frank" Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm's future strategy and research and development (R&D) layout.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23218\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23218\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T11:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T11:48:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO\",\"datePublished\":\"2023-01-03T11:44:00+00:00\",\"dateModified\":\"2025-01-26T11:48:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"CStone Pharmaceuticals\",\"Hengrui Pharmaceuticals\",\"HKG: 2616\",\"SHA: 600276\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23218#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23218\",\"name\":\"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-03T11:44:00+00:00\",\"dateModified\":\"2025-01-26T11:48:57+00:00\",\"description\":\"China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. \\\"Frank\\\" Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm's future strategy and research and development (R&D) layout.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23218\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23218#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. \"Frank\" Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm's future strategy and research and development (R&D) layout.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23218","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23218","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-03T11:44:00+00:00","article_modified_time":"2025-01-26T11:48:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23218#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23218"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO","datePublished":"2023-01-03T11:44:00+00:00","dateModified":"2025-01-26T11:48:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23218"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","CStone Pharmaceuticals","Hengrui Pharmaceuticals","HKG: 2616","SHA: 600276"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23218#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23218","url":"https:\/\/flcube.com\/?p=23218","name":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-03T11:44:00+00:00","dateModified":"2025-01-26T11:48:57+00:00","description":"China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. \"Frank\" Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm's future strategy and research and development (R&D) layout.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23218#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23218"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23218#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23218"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23218\/revisions"}],"predecessor-version":[{"id":23219,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23218\/revisions\/23219"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}